Stems Cells in general what's companies are doing covid!
MultiStem therapy: Athersys will initiate a phase 2/3 study to assess the safety and efficacy of its stem cell product candidate for the treatment of acute respiratory distress syndrome induced by COVID-19. First clinical sites for the MultiStem Administration for COVID-19 Induced ARDS (MACOVIA) study are expected to open in the second quarter of 2020.
Remestemcel-L: Mesoblast Limited is investigating its allogeneic mesenchymal stem cell (MSC) product candidate, as a treatment for patients with acute respiratory distress syndrome caused by COVID-19. Remestemcel-L, which is composed of culture-expanded MSCs derived from the bone marrow of an unrelated donor, is administered in a series of intravenous infusions and is believed to have immunomodulatory properties to counteract inflammatory processes. A randomized, placebo-controlled trial is being conducted at Mount Sinai hospital in New York City.
Market Data 
Markets 
AI
